ArticleComprehensive Physiology2026
Inhaled 5-HT
Article in Comprehensive Physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trigeminal neuralgia: from clinical challenges to molecular insights.The journal of headache and pain · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundSumatriptan, an antimigraine drug, is known to cause adverse chest symptoms such as dyspnea and chest tightness. We previously showed that sumatriptan sensitized capsaicin-sensitive lung vagal (CSLV) afferents in rats, a mechanism potentially underlying these symptoms. This sensitizing effect was abolished by intravenous GR127935, a 5-HT
methodsExperiments were performed in anesthetized male Brown-Norway rats. CSLV-afferent excitability and afferent-mediated airway reflexes were assessed using single-fiber recordings and respiratory pattern monitoring. The antimigraine efficacy of sumatriptan was evaluated based on its inhibitory effect on dural plasma protein extravasation evoked by unilateral electrical stimulation of the trigeminal ganglion.
resultsIntravenous sumatriptan potentiated capsaicin-evoked CSLV-afferent discharges and afferent-mediated airway responses. However, pretreatment with inhaled GR127935 significantly blocked this potentiating effect. The sumatriptan's antimigraine efficacy was not affected by inhaled GR127935, but was reduced by intravenous GR127935. Consistently, intravenous, but not inhaled GR127935, altered sumatriptan-induced hypotension, indicating that pulmonary delivery minimized systemic effects. Moreover, inhaled GR127935 did not change baseline cardiorespiratory parameters or fiber activity, suggesting it is unlikely to cause adverse cardiorespiratory effects.
conclusionsInhalation of a 5-HT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.